Abstract
Objective: to study the clinical significance of P-glycoprotein (P-gp) in breast cancer. Methods: Expression of P-gp in 60 cases of breast cancer was examined by immunohistochemistry. P-gp expression and response to chemotherapy were comparatively investigated in 19 patients with metastatic breast cancer. Results: The P-gp was positive in 48.3% of the 60 cases of breast cancer. P-gp expression was not related to patients' age, menstruation status, number of axillary lymph nodes involved, clinical stage, histological type, and hormonal receptor status (P>0.05). The frequency of metastasis (62.1%) and mortality (51.7%) were higher in P-gp positive cases than in negative cases (16.1% vs 12.9%, P<0.005). The 5-year survival rate of P-gp positive cases (48.3%) was significantly lower than that of negative cases (87.1%) (P<0.05). In patients who received adjuvant chemotherapy distant metastasis occurred more frequently in the P-gp positive cases (94.7%) than in the P-gp negative cases (57.1%) (P=0.0468). More P-gp negative patients (7/9) than positive patients (1/10) were responsive to chemotherapy (P=0.0055). Conclusion: Immunohistochemical examination of P-gp expression is useful in predicting response to chemotherapy and prognosis in breast cancer patients. P-gp positivity is associated with poor prognosis.
Similar content being viewed by others
References
Lenoardo E, Valente G, Cappia S, et al. Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994; 57:841.
Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994; 86:1539.
Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high ki 67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 1995; 36:61.
Wallner J, Depisch D, Hopfner M, et al. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 1991; 27:1352.
Gregorcyk S, Kang Y, Brandt D, et al. P-glycoprotein expression as a predictor of breast cancer recurrence. Ann Surg Oncol 1996; 3:8.
Ro J, Sahin A, Ro JY, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21:787.
Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83:111.
Botti G, Chiappetta G, D'Aiuto G, et al. PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. Tumori 1993; 79:214.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
En-xiao, L., Rong, L., Zhen-hua, Z. et al. Clinical significance of P-glycoprotein expression in breast cancer. Chin. J. Cancer Res. 11, 218–220 (1999). https://doi.org/10.1007/s11670-999-0017-8
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11670-999-0017-8